Payment overview · 2025
General Payments
$547.80
24 reported records · 14 companies
Healthcare provider profile · identity verified
H Keith Weiss, DO
Allopathic & Osteopathic Physicians|Family Medicine · CHRISTIANA, PA · NPI 1568420669
Verified facts
What the public records show
CMS Open Payments records show H Keith Weiss, DO received $547.80 in general payments during 2025 across 24 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $84.07 | 15.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.44 | 12.5% | 3 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $46.98 | 8.6% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $45.26 | 8.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.26 | 8.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.21 | 7.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.27 | 7.5% | 2 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $37.51 | 6.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.15 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.12 | 4.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.28 | 4.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.96 | 3.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.91 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.38 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $547.80 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $46.98 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.26 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.26 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $45.26 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.30 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.21 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.77 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.27 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.47 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $37.51 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 173 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 129 | 24 |
| Metformin Hcl | Metformin Hcl | 124 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 83 | 15 |
| Lisinopril | Lisinopril | 82 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 13 |
| Simvastatin | Simvastatin | 70 | 15 |
| Furosemide | Furosemide | 59 | 11 |
| Omeprazole | Omeprazole | 58 | suppressed |
| Jardiance | Empagliflozin | 57 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | suppressed |
| Losartan Potassium | Losartan Potassium | 52 | 11 |
| Meloxicam | Meloxicam | 50 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 15 |
| Ibuprofen | Ibuprofen | 47 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Lactulose | Lactulose | 33 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Gabapentin | Gabapentin | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 12 |
| Diazepam | Diazepam | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $547.80 · 24 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | Auvelity, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, JOURNAVX, LUPKYNIS, MOUNJARO, Ohtuvayre, Ozempic, RELISTOR, REXULTI, Rybelsus, SUBLOCADE, TARPEYO, VRAYLAR, XIFAXAN, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error